Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.

Also called NCT04504370

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 273 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04504370
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04504370. Randomized; quadruple masking; primary purpose treatment. Start 2020-04-27 (actual); primary completion 2022-03-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
Acronym
PB119
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
GLP-1 receptor agonist
Intervention (Drug)
Placebo
Lead sponsor
PegBio Co., Ltd. (class: other)

Record details

Record id
cardio:ct-nct04504370
Content hash
d8c4175b289411fe8edbd91d64406b5f98b597b011b93edc6b9ae1633946c38d